trusight oncology

Pan-cancer biomarker NGS assay

trusight oncology


TruSight Oncology 500 offers wide variety of benefits in analyzing multiple tumor variant types in 523 genes in a single assay. It is a next-generation sequencing (NGS) assay that enables comprehensive genomic profiling of tumor samples. The assay is highly effective in identifying all types of relevant DNA and RNA variants in different types of solid tumors including lung, melanoma, ovarian, breast, gastric, bladder, sarcoma etc.

The assay is also highly accurate in measuring immuno-oncology biomarkers such as microsatellite instability (MSI) and tumor mutational burden (TMB).

Download whitepaper

trusight oncology services

Trusight oncology Applications

Solutions for cells, blood, tissues, FFPE, ctDNA with varying quality and quantity inputs

MedGenome Tissue
  • Single comprehensive NGS assay to target 523 key immuno-oncology biomarkers for assessment of all DNA and RNA variant types, plus MSI and TMB.
  • Sample-to-data workflow in 5-7 days using target enrichment on as little as 50 ng of purified DNA and RNA.
  • Amount of sample needed for ctDNA Purified: >100ng ctDNA in 15-20µl.
  • TSO 500 data with Dragen and Illumina Connected Insights for the highest accuracy and fastest analysis time.


White papers and technical resources

Comprehensive genomic profiling of clinically relevant cancer genes with Illumina's TruSight Oncology 500 (TSO 500) NGS assay


Other services you'll be interested in


Featured articles

PacBio Revio full-service capability


MedGenome enhances omics insights with in-house PacBio Revio full-service capability
Grant Winner Dr. Lauren Esposito


MedGenome announces de novo Genome Assembly and Annotation Grant winners for 2024
Foster City Award


MedGenome Inc., honored with the Best of Foster City Award six times in a row
Martin Dewhurst MedGenome


MedGenome appoints Martin Dewhurst as Chairman of Advisory Board
10X Certified MedGenome


MedGenome achieves 10x Genomics Certified Service provider qualification for single cell sequencing
MedGenome Pharma Partneship


MedGenome ties-up with Emmes to bridge gaps in rare diseases
MedGenome Grant


MedGenome, in collaboration with PacBio, announces a de novo genome assembly and annotation grant
Biomarker Discovery Research


Gallbladder cancer vaccine candidates identified


Work with the multiomics specialists

Fields marked * are mandatory

    ©2024 MedGenome | All rights reserved | Terms & conditions | Privacy policy
    Request a quote